Unknown

Dataset Information

Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.


ABSTRACT:

Aims

Erythropoiesis-stimulating agents used to treat anaemia in patients with chronic kidney disease (CKD) have been associated with cardiovascular adverse events. Hepcidin production, controlled by bone morphogenic protein 6 (BMP6), regulates iron homeostasis via interactions with the iron transporter, ferroportin. High hepcidin levels are thought to contribute to increased iron sequestration and subsequent anaemia in CKD patients. To investigate alternative therapies to erythropoiesis-stimulating agents for CKD patients, monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively, were tested in CKD patients.

Methods

Preclinical in vitro/vivo data and clinical data in healthy subjects and CKD patients were used to illustrate the translation

SUBMITTER: Sheetz M 

PROVIDER: S-EPMC6475730 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature